AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03239236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid sequence induction m-RSI-vent
Description: Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
Study NCT03239236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: m-RSI-vent-cric
Description: Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
Study NCT03239236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricoid Pressure
Description: Cricoid Pressure will be applied during RSI until laryngoscopy
Study NCT03239236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics
Description: Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
Study NCT03239236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aspiration of gastric air via nasogastric tube
Description: A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
Study NCT06042439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 weeks of exercise training (Post-training)
Description: handgrip and treadmill walking 4 days per week
Study NCT03239236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Impression of gastric inflation at laparoscopy.
Description: The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
Study NCT03239236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arterial blood gas
Description: Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
Study NCT05008588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioned Medium
Description: Intranasal of 3 cc of conditioned medium each, for 3 days in a row
Study NCT05008588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
Study NCT05008588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurologic and Neutrophic Drugs
Description: Such as clopidogrel, piracetam, citicoline
Study NCT05019040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: TDF as control
Study NCT05116514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months
Study NCT06400316 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement
Description: The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.
Study NCT05236881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANíMATE mobile application
Description: mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
Study NCT06263556 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pelvic floor exercises
Description: Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day
Study NCT05650424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage training
Description: please refer to group description
Study NCT05650424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal massage training
Description: please refer to group description
Study NCT05260723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Sit Less
Description: The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
Study NCT06213324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
Study NCT06213324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline delivered intravenously
Study NCT05949255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 10 subject will receive a probiotic daily for 12 weeks.
Study NCT05949255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects will receive a placebo daily for 12 weeks.
Study NCT05415150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombolytic Agent
Description: Subjects may receive one or more of the treatment options
Study NCT05528874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes
Description: Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
Study NCT05528874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crossover: Recipe 4 before recipe 5
Description: After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner.
Study NCT05528874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crossover: Recipe 5 before recipe 4
Description: Same as previous group, but starting with recipe 5
Study NCT04942938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neubie
Description: The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
Study NCT05904249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Based Synchronized Telerehabilitation
Description: Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching
Study NCT05904249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-Face Rehabilitation
Description: Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching
Study NCT05341804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive and balance dual task training
Description: a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
Study NCT05341804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: Includes static balance, dynamic balance and strength training
Study NCT04786964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT06461611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Diary Program
Description: The health diary is constructed based on the theory of health action process approach, which is used to plan and clock for self-management behaviors of adolescent patients during fixed orthodontic treatment.
Study NCT06461611 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Health Education
Description: Traditional health education is that the nurse orally teaches the patient about fixed orthodontic knowledge, and the patient obtains a paper information.
Study NCT04786964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study NCT04786964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Study NCT04786964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT06070805 — intervention group
Intervention type: OTHER
Intervention: depression
Description: The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
Study NCT05494216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
Study NCT04786964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study NCT04786964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT05494216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MACS
Description: Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
Study NCT04786964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study NCT06527456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participation of the general practitioner
Description: participation of the general practitioner in encouraging cervical cancer screening
Study NCT05338957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002+HX008
Description: Administrated intravenously
Study NCT06174363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maxigesic
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.
Study NCT06174363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
Study NCT06450691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: skin biopsy and blood sampling
Study NCT05525338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
Study NCT06080776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028 tablets
Description: The initial dose of SH-1028 tablets is 200 mg once daily.
Study NCT06080776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SH-1028 tablets
Description: Placebo SH-1028 tablets.
Study NCT05633147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan glurate
Description: Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days.
Study NCT05633147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug drug interaction (DDI) - Clarithromycin (Part I)
Description: Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
Study NCT05633147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug drug interaction (DDI) - Midazolam (Part 2)
Description: Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
Study NCT05942157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Description: Upon randomization and before the bacterial culture results are known, blood sampling will be obtained from the patient during the morning round of initial empiric antibiotic administration. PK/PD target analysis based on the clinical susceptibility breakpoints of Enterobacterales (the most prevalent organism family of DT-GNB infections in our setting) will be performed and a dosage recommendation will be communicated to the primary ID clinician. Antibiotic dosing adjustments (if any) will be made within 8 - 24 hours of the blood sampling by the Primary / Infectious Diseases clinician. In case of inappropriate dosing, where the PK/PD target is not achieved or exceeded with antibiotic side effects observed, the dosage will be increased or decreased, respectively.
Study NCT04869709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Sodium Phosphate
Description: Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
Study NCT06013995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days
Study NCT06013995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days
Study NCT05327855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPL-0301 Dose 1
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Study NCT05327855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPL-0301 Dose 2
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Study NCT05327855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
Study NCT06271304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue blocking eyewear
Description: Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
Study NCT06271304 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low filtration eyewear
Description: Eyewear is worn daily from 6 PM to 8 AM during manic/hypomanic state Eyewear is worn daily 2 hours before planned bedtime during euthymic, depressive and mixed state
Study NCT06203197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients in the intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS)
Description: intervention group will use the mobile-based care support application (M-Breast cancer personal care and monitoring system (M-MEKKBİS).
Study NCT05777317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 kHz SCS
Description: Spinal cord stimulation programmed to a frequency of 10 kHz
Study NCT05777317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMM alone
Description: Conventional medical management alone
Study NCT04813952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane inhalant product
Description: The sevoflurane dose differed in both groups in relation to the fresh gas flow. Since the fresh gas flow is less in group M, the concentration of sevoflurane consumed by the patient at the end of the case will be less.
Study NCT04206215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
Study NCT04206215 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
Study NCT04206215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study NCT04206215 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study NCT04979988 — intervention group
Intervention type: DRUG
Intervention: Lortlatinib
Description: as provided in real world practice